pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
280
stories
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 5, 26
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
Aug 4, 26
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
Aug 3, 26
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Aug 3, 26
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
Jul 31, 26
AbbVie touts strong momentum for Skyrizi despite rising competition
endpoints
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
Jul 30, 26
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
Jul 30, 26
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
Jul 30, 26
Sanofi records €1B+ write-off, ends work on two immunology assets
endpoints
Jul 30, 26
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
Jul 30, 26
GSK pens $110M biological datasets pact with AI biotech Relation
fiercebiotech
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
Jul 29, 26
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
Jul 29, 26
Do you need oncology experience to land an oncology job?
biospace
Jul 29, 26
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
fiercebiotech
Jul 28, 26
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
Jul 27, 26
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
biopharma dive
Jul 27, 26
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
Jul 27, 26
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
Jul 27, 26
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
Jul 27, 26
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
Jul 27, 26
STAT+: Argenx to buy Forte Biosciences for $2.2B
stat
Jul 27, 26
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
fiercebiotech
Jul 24, 26
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
Jul 24, 26
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
← prev
page 8 of 10
next →